Plain-English translation of NCT06043973 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing whether combining two medications— and anlotinib—can help people with advanced non-small cell lung cancer (NSCLC) that has specific genetic changes. Right now, doctors typically use one targeted drug at a time for this type of cancer, but this study wants to see if using both together might work better and help people live longer and feel better.
Standard single-drug treatments can help some patients, but people whose cancer has both an EGFR mutation and a TP53 mutation may not benefit as much. Researchers believe that combining two medications might overcome this limitation and improve survival and quality of life for these patients, but more evidence is needed.
You likely qualify if…
You likely don't qualify if…
You would take as a daily pill (110 mg) and anlotinib as a pill taken for 2 weeks followed by 1 week off, repeating in 3-week cycles. You would continue this treatment until your cancer stops responding or the side effects become too difficult to manage. Throughout the study, you would have regular clinic visits to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China